Metoprolol Succinate Sustained-release Tablets Research Articles

FORMULATION AND EVALUATION OF CONTROLLED RELEASE METOPROLOL SUCCINATE MATRIX TABLET USING NATURAL WAXES FOR THE MANAGEMENT OF HYPERTENSION

Metoprolol succinate is a cardioselective β-blocker used in the management of secondary hypertension complications. Metoprolol succinate is prescribed to suppress the hypertension condition and to minimize the cardiac-related disorder. In the present study, metoprolol succinate sustained-release tablets were successfully prepared by the wet granulation method. Carnauba and beeswax as natural resources were used as drug release modifying polymers in varying ratios of 1:0, 0:1, and 1:1 respectively. All developed tablets were passed the uniformity of weight, friability, uniformity of thickness, and uniformity of diameter test respectively. The crushing strength of formulated tablet was in ranges of 1.4 to 2.4megapascal (MPa) and showed the optimum tensile strength. The formulated tablet's percentage of drug content and content of uniformity had97.50 and 99.24.The formulated batch F3 (ratio of 1:0) which are capable for provide the desirable drug release over a twelve hours period. The stability study shows the formulation batch F3 was stable. Therefore, this formulation method is economically it may be suitable for the pharmaceutical industries to use this type of simple technology for the development of advanced formulations.

Diagnosis of spontaneous isolated superior mesenteric artery dissection with ultrasound: A case report

BACKGROUNDSpontaneous isolated superior mesenteric artery dissection (SISMAD) is a rare disease that originates from the superior mesenteric artery, without the presence of aortic and other arterial dissections. Most cases are diagnosed using contrast-enhanced computed tomography (CECT), whereas the application of ultrasound is less common.CASE SUMMARYHere, we report a case of SISMAD with sudden epigastric pain that worsened as the main symptom after eating. The patient had a long history of hypertension with unknown blood pressure control but no history of smoking or alcohol consumption. This case was initially diagnosed using ultrasound and the results were later confirmed by CECT. After admission, the patient fasted, followed by parenteral nutrition support and fluid supplementation to maintain electrolyte and acid–base balance. Metoprolol succinate sustained-release tablets and aspirin were given as nonoperative treatments. After 1 wk, the symptoms improved, and the patient was discharged. During telephone follow-up, the patient did not develop similar symptoms. CONCLUSIONWhether ultrasound can be used as a routine and noninvasive imaging method for the diagnosis of SISMAD needs further exploration.

Formulation Development and In-vitro Evaluation of Sustained Release Tablets of Metoprolol Succinate

Metoprolol succinate is a β1 selective antagonist used an anti-arrhythmic, antiagina, antihypertensive. sustained release tablet of metoprolol succinate were formulated using polymers. The half-life of drug is relatively 4-6 hours. The formulation of metoprolol succinate tablet were produced by direct compression or wet granulation method. The formulations were evaluated for thickness, hardness, weight variation, friability and dissolution, drug content all the physical characteristics of the formulated tablets were within acceptable limits. The dissolution studies of Metoprolol succinate sustained release tablets reflects USP specification NMT 25%by 1 hours, 20-40%by 4 hours,40-60%by 8 hours and more than 80% by 20 hrs.

Efficacy of Metoprolol Succinate Sustained Release Tablets Combined with Wenxin Granules in the Treatment of Coronary Heart Disease Arrhythmia

Objective: To explore the effect of metoprolol succinate sustained-release tablets combined with Wenxin Granules in the treatment of coronary heart disease patients with arrhythmia. Methods: The research objects were 50 patients with arrhythmia who were treated in our hospital from September 2019 to September 2020. According to different treatment methods, they were divided into observation group (Wenxin Granule + metoprolol succinate treatment) and control group (metoprolol succinate treatment), 25 cases in each group. The curative effects of the two groups were compared. Results: After treatment, there was no significant difference in rnn50, RMSSD, sdnni and SDANN between the two groups (P>0.05). Compared with the control group, the SDNN in the observation group was higher than that in the control group (P< 0.05); Before treatment, there was no significant difference in the above indexes between the two groups (P>0.05); The effective rates of the observation group and the control group were 92.00% and 68.00% respectively, and the curative effect of the observation group was higher than that of the control group (P< 0.05); There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: In the treatment of patients with coronary heart disease and arrhythmia, Wenxin Granule Combined with metoprolol succinate sustained-release tablets has significant effect, which can effectively improve the dynamic electrocardiogram indexes of patients, improve the clinical efficacy, and has high safety.

Clinical Efficacy of Metoprolol Succinic Acid Sustained Release Tablets Combined with Trimetazidine in the Treatment of Gastrointestinal Tumors with Angina Pectoris

Objective: To investigate the clinical efficacy of metoprolol succinate sustained-release tablets combined with trimetazidine in the treatment of gastrointestinal tumors with angina pectoris. Methods: We enrolled the 58 patients with digestive tract tumor merger angina in November 2017 - October 2019 and analysis the hospital clinical data by retrospective method. We included patients with routine treatment in control group (n = 31 cases) and the subjects treated with increased dose of succinic acid metoprololzyban joint with trimetazidineinobservation group (n = 27 cases) according to the different treatment group. Results: The effective rate of angina pectoris treatment in the observation group was higher than that in the control group. Furthermore, the incidence of adverse reactions was lower than that in the control group and the difference was statistically significant (P < 0.05). Conclusion: Metoprolol succinic acid sustained release tablets combined with trimetazidine in the treatment of gastrointestinal tumors with angina pectoris can improve the efficacy of angina pectoris. The drug use is safe and worthy of clinical use.

Static and dynamic structural features of single pellets determine the release behaviors of metoprolol succinate sustained-release tablets

The multiple-unit sustained-release (MUSR) dosage forms containing numerous sustained-release subunits present a reliable choice for oral formulation of controlled release systems. As a typical MUSR, the metoprolol succinate sustained-release tablet is an advanced system with limited researches devoted to relating its structure to the drug release phase other than the preparation process and modulation to the release behaviors. This research details a three-dimension method to image the internal structure and detail drug release features of commercial metoprolol succinate sustained-release tablets and component individual single pellets. As such, a new perspective for MUSR dosage form is provided. Using high energy synchrotron radiation X-ray microcomputed tomography (SR-μCT), the in-situ structure parameters were obtained nondestructively. It was demonstrated that the average number of spherical pellets in a tablet was 853 ± 12 (n = 3). The average volume of the pellets was 0.09 ± 0.01 mm3, the diameter was 0.55 ± 0.03 mm, and the sphericity was 0.87 ± 0.06. These data reflected the numerical features of pellets in MUSR tablets, which were helpful for reverse engineering to MUSR. Based on the three dimensional model generated by image processing and analysis software, the pellet structures were divided into three layers of typical depot sustained release system: pellet core, drug-containing layer and outer film. The dynamic structural features determined refer to the changes of structures in pellets during in vitro drug release, with evidence that the coating layer on the pellets maintained a spherical morphology whilst numerous valleys appeared on the surface. The material constitution and distribution in coating layer were evaluated by synchrotron radiation-based Fourier transform infrared mapping and results indicated a composition of hydroxypropyl methylcellulose dispersed in ethyl cellulose. Knowledge of these structural characteristics confirmed that the mechanism of sustained drug release was membrane controlled and consistent with the drug release profiles. In conclusion, the structural investigation provided knowledge of the intrinsic quality of metoprolol succinate sustained-release tablets and offers guidance for reverse engineering of MUSR.

Impact of CYP2D6 and ADRB1 polymorphisms on heart rate of post-PCI patients treated with metoprolol.

Aim: To explore the effect of CYP2D6*10 (100C>T) and ADRB1 1165 G>C polymorphisms on heart rate of post-PCI (percutaneous coronary intervention) patients treated with metoprolol succinate sustained-release tablets. Methods: A total of 756 inpatients with metoprolol succinate sustained-release tablets were selected and the genotypes of CYP2D6*10 and ADRB1 1165G>C were detected in 319 patients using gene chip detection. The target heart rate was defined as a resting heart rate<70beats/min. Clinical data were collected. Results: A total of 319 inpatients were enrolled in the study. The mutant allele frequencies of CYP2D6 and ADRB1 were 57.21 and 69.44%, respectively. Whatever the dose of metoprolol, the heart rates were lower in patients with homozygous mutation of CYP2D6 than those with heterozygous mutation and wild-type (p<0.05). Nevertheless, this effect was not seen between different genotypes of ADRB1. Logistic regression analysis showed that the dose of metoprolol and the genotypes of CYP2D6 were predictors of heart rate<70beats/min in these patients. Further multivariate analysis indicated that patients with homozygous mutation had better control of heart rates compared with those with wild-type and heterozygous mutation of CYP2D6*10 genotypes (all: p<0.001). Conclusion:CYP2D6*10 polymorphisms were associated with the heart rate of post-PCI patients treated with metoprolol succinate sustained-release tablets.

ASSA14-07-02 Comparision of metoprolol succinate sustained-release tablets and metoprolol tartrate tablets on cardiac function in patients with chronic congestive heart failure

Background To investigate the effect of Metoprolol succinate sustained-release tablets and Metoprolol tartrate tablets on cardiac in chronic congestive heart failure patients. Methods 182 patients with clinical data, who suffered with chronic congestive heart failure were collected, and 67 cases were excluded. The patients were divided into 2 groups according to the different types of dosage forms: Metoprolol succinate sustained-release tablets group and Metoprolol Tartrate Tablets group. Patients in Metoprolol Tartrate Tablets group took 25 mg-50 mg Metoprolol Tartrate Tablets every day, while patients in the other group took 23.75–95 mg metoprolol succinate sustained-release tablets every day. Average heart rate, LVDd, EF, BUN and Crea were measured. Results Compared with Metoprolol Tartrate Tablets, Metoprolol succinate sustained-release tablets decreased average heart rate in chronic congestive heart failure patients (64.0 ± 5.4 vs 69.5 ± 7.6, p Conclusions Metoprolol succinate sustained-release tablets decreased average heart rate in chronic congestive heart failure patients compared with Metoprolol Tartrate Tablets. The effect on cardiac and renal function was equal.

The analysis of 60 patients of essential hypertension treatment with metoprolol succinate sustained-release tablets

ObjectiveTo observe the effects of metoprolol succinate sustained-release tablets in treating mild to moderate essential hypertension.MethodsSixty adults with mild and moderate essential hypertension were randomly divided into two groups of...

The effects of various antihypertensive drug treatment on pulse wave velocity in patients with essential hypertension

Objective To evaluate the effects of various antihypertensive drug treatment on Brachialankle pulse wave velocity(baPWV) in patients with essential hypertension.Methods 120 patients with essential hypertension were randomly divided into four group treated various antihypentive drug.Group A 30 cases( levamlodipine besylate 2.5 mg once daily),group B 30 cases(perindopril 4 mg once daily),group C 30 cases ( metoprolol succinate sustained-release tablets 47.5 mg once daily),group D 30 cases(valsartan 80 mg once daily) for twelve weeks and thirty health persons with normal blood pressure as the control group.The levels of serum blood lipid and blood glucose,systolic blood pressures(SBP),diastolic blood pressures(DBP)and baPWV were measured respectively in patients with essential hypertension and healthy persons with normal blood pressure.After twelve weeks treatment respectively,the SDP,DBP and baPWV were measured again and were studied in patients with essential hypertension.Results The level of total blood cholesterol(TC) and low-density lipoprotein cholesterol(LDL-C) and SBP,DBP and baPWV in patients with essential hypertension were higher significantly than that of healthy persons with normal blood pressure(P ＜ 0.05).There were no significant difference in levels of blood glucose in patients with essential hypertension and control group(P ＞ 0.05).The SBP,DBP and baPWV were decreased significantly in all four groups( P ＜ 0.05)after treatment.There were significant difference in reduction of systolic blood pressures(△SBP)(30.6 ± 6.7) mm Hgvs(20.7 ± 5.3) mm Hg、(19.6 ± 6.1) mm Hg 、(21.5 ± 4.3) mm Hg and of diastolic blood pressures(/ DBP)(20.8 ± 7.1) mm Hgvs(13.97 ± 7.6) mm Hg、(14.1 ± 6.8) mm Hg、(14.9 ± 4.2) mm Hg in levamlodipine besylate group and the other three groups(P ＜ 0.05).Conclusion levamlodipine besylate,perindopril,metoprolol succinate sustained-release tablets and valsartan can decreased pulse wave velocity,impore elasticity of large arterise and increase the distensibility of aorta in patients with essential hypertension Key words: Essential Hypertension; Pulse wave velocity; Evamlodipine besylate; Perindopril; Metoprolol succinate sustained-release tablets

Effects of metoprolol succinate sustained-release tablets on pulse wave velocity in patients with essential hypertension

Objective To evaluate the effects of metoprolol succinate sustained-release tablets on Brachial-ankle pulse wave velocity(baPWV) in patients with essential hypertension.Methods The levels of serum blood lipid and blood glucose,blood pressure,heart rate and baPWV were measured respectively in twenty-eight patients with essential hypertension and twenty-eight healthy persons with normal blood pressure.After twelve weeks treated with metoprolol succinate sustained-release tablets,The blood pressure and baPWV were measured again and were studied in patients with essential hypertension.Results The systolic blood pressure (156.3 ±8.6) mm Hg vs (112.6 ± 11.9) mm Hg,diastolic blood pressure (103.6 ± 6.7) mm Hg vs (68.2 ± 8.9) mm Hg and baPWV(1971.3 ± 187.4)cm/s vs(1187.2 ± 198.5)cm/s in patients with essential hypertension were higher than that of healthy persons with normal blood pressure significantly(P ＜ 0.05),The heart rate (85.2 ±4.7) vs (64.5 ± 6.3) beat/min,systolic blood pressure (156.3 ± 8.6) mm Hg vs (121.9 ± 7.9) mm Hg,diastolic blood pressure(103.6 ± 6.7) mm Hg vs (76.3 ± 5.1) mm Hg and baPWV (1971.3 ± 187.4) cm/s vs (1236.5 ± 186.3)cm/s were decreased significantly in patients with essential hypertension(P ＜ 0.05)after treated with metoprolol succinate sustained-release tablets.Conclusion Metoprolol succinate sustained-release tablets treated in patients with essential hypertension can decreased pulse wave velocity,impore elasticity of large arterise and increase the distensibility of aorta. Key words: Hypertension; Pulse wave velocity; Metoprolol succinate sustained-release tablets

Influenc of Metoprolol Succinate Sustained-release Tablets therapy on ventricular rate and heart function of patients with chronic atrial fibrillation and chronic heart failure

Objective To study the influenc of metoprolol succinate sustained-release tablets therapy on ventricular rate and heart function of patients with chronic atrial fibrillation(CHF)and chronic heart failure(HF).Methods A total of 69 patients with chronic atrial fibrillation and chronic heart failure were randomly divided into treatment group(35 cases)and control group(34 cases).The general therapy included digoxin,diuretics,angiotensin-converting enzyme inhibitors(ACEI)or angiotensin-Ⅱ-receptor antagonists(ARB)and anticoagulants for a 6-momth follow-up period.The patients of treatment group was treated with metoprolol succinate sustained-release tablets above the base of the general therapy.The ventricular rate at rest and the ventricular rate after 6-minute walk,left ventricular end diastolic dimension(LVEDD),left ventricular end systolic dimension(LVESD),left ventricular ejection fraction(LVEF)and the distance of 6-minute walk were examined before and 6 months after therapy.After 6 months,to compare the changes of clinical manifestations.Results ①The ventricular rate at rest decreased significantly in both two groups(P＜0.01),the ventricular rate after 6-minute walk decreased significantly in treatment group 6 month after treatment(P＜0.01),but there was no significant difference betwen before and after treatment in control group on the ventricular rate after 6-minute walk(P＞0.05),and the ventricular rate after 6-minute walk was decreased more in tretment group than that in control group(P＜0.01).②The LVEF,LVEDD,LVESD and the distance of 6-minute walk in both groups had significant improvement as compared with before treatment(P＜0.01～0.05),with the treatment group showing a better improvement than in control group(P＜0.05).③The total responsive rate in the treatment group(93.8%)was significantly higher than in control group(77.4%)(P＜0.05).Conclusion Based on the medication of digitalis,diuretics and ACEI or ARB,metoprolol succinate sustained-release tablets therapy can effectively control ventricular rate,significantly improve heart function and also reverse left ventricular in patients with chronic atrial fibrillation and chronic heart failure. Key words: Metoprolol succinate; Chronic atria; Heart failure; Ventricular rate